<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574287</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00051415</org_study_id>
    <nct_id>NCT01574287</nct_id>
  </id_info>
  <brief_title>Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas</brief_title>
  <official_title>Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David M. Schuster, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperparathyroidism (excessive production of parathyroid hormone (PTH) usually caused by a
      small growth called an adenoma in the parathyroid glands) is an increasingly significant
      medical and public health condition.

      Surgery is the only effective management for primary hyperparathyroidism. However; it is
      sometimes difficult to pinpoint the adenoma, in part because current methods of imaging often
      fail to identify the parathyroid adenoma in as many as 30% of patients. In reoperative
      parathyroidectomy for persistent or recurrent hyperparathyroidism, localization plays an even
      greater role. Unfortunately current multiple imaging methods fail to localize 10-15% these of
      tumors.

      SPECT/CT with the radiotracer 99mTc sestamibi has become the standard method for pinpointing
      the tumor. This, however, is a challenge because the parathyroid glands usually are located
      close to the thyroid and the radiotracer 99mTc sestamibi concentrates both in thyroid and
      parathyroid tissue. Hence there is a need for a tracer/imaging tool that concentrates in the
      parathyroid but not in the thyroid.

      A more sensitive and specific radiotracer/tracking agent would markedly improve the
      investigators ability to identify parathyroid tumors preoperatively, and thus offer more
      patients a minimally invasive parathyroidectomy.

      anti-3-[18F]FACBC is an amino acid based PET radiotracer which has shown utility in detecting
      a variety of tumors. In cell culture experiments, anti-3-[18F]FACBC has shown uptake in
      parathyroid cells greater than thyroid cells. Therefore, the investigators think that this
      radiotracer may be able to help us identify parathyroid adenomas better than 99mTc sestamibi.

      The primary aim of this study is to determine if anti-3-[18F]FACBC PET-CT demonstrates uptake
      within parathyroid adenomas. 12 patients with a diagnosis of primary hyperparathyroidism will
      undergo PET-CT using anti-3-[18F]FACBC in addition to the standard 99mTc sestamibi scanning
      and other imaging as clinically appropriate such as ultrasound, MRI, and/or contrast enhanced
      CT scanning. Since all these patients undergo surgery routinely, the investigators will then
      compare findings at surgery to those of the anti-3-[18F]FACBC PET-CT to determine if this
      radiotracer is worthy of further study in a more comprehensive experiment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality</measure>
    <time_frame>At approximately 1 month post scan (time of surgery and pathologic analysis)</time_frame>
    <description>Detection rate of parathyroid adenomas using anti-3-[18F]FACBC modality is assessed by comparing [18F]FACBC and surgical findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target-to-background Ratio (TBR) of Anti-3-[18F]FACBC for Blood Pool</measure>
    <time_frame>5-10 min after intravenous bolus injection of [18F]fluciclovine</time_frame>
    <description>To evaluate uptake mechanisms of anti-3-[18F]FACBC, target-to-background ratio (TBR) of anti-3-[18F]FACBC is assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Parathyroid Disease</condition>
  <arm_group>
    <arm_group_label>FACBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FACBC</intervention_name>
    <description>Drug is give intravenously over 2 minutes at time of scan</description>
    <arm_group_label>FACBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be 18 years of age or older.

          2. Patients will have biochemical and/or clinical evidence of primary hyperparathyroidism
             and be a surgical candidate for definitive parathyroid surgery .

          3. Ability to lie still for PET scanning

          4. Patients must be able to provide written informed consent

        Exclusion Criteria:

          1. Age less than 18.

          2. Inability to lie still for PET scanning.

          3. Cannot provide written informed consent.

          4. History of secondary hyperparathyroidism.

          5. Positive serum or urine pregnancy test within 24 hours of imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 31, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <results_first_submitted>June 14, 2019</results_first_submitted>
  <results_first_submitted_qc>June 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>David M. Schuster, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Parathyroid Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 22, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01574287/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01574287/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FACBC</title>
          <description>FACBC: Drug is give intravenously over 2 minutes at time of scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FACBC</title>
          <description>FACBC: Drug is give intravenously over 2 minutes at time of scan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality</title>
        <description>Detection rate of parathyroid adenomas using anti-3-[18F]FACBC modality is assessed by comparing [18F]FACBC and surgical findings.</description>
        <time_frame>At approximately 1 month post scan (time of surgery and pathologic analysis)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FACBC</title>
            <description>FACBC: Drug is give intravenously over 2 minutes at time of scan</description>
          </group>
        </group_list>
        <measure>
          <title>Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality</title>
          <description>Detection rate of parathyroid adenomas using anti-3-[18F]FACBC modality is assessed by comparing [18F]FACBC and surgical findings.</description>
          <units>percentage of adenomas detected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target-to-background Ratio (TBR) of Anti-3-[18F]FACBC for Blood Pool</title>
        <description>To evaluate uptake mechanisms of anti-3-[18F]FACBC, target-to-background ratio (TBR) of anti-3-[18F]FACBC is assessed</description>
        <time_frame>5-10 min after intravenous bolus injection of [18F]fluciclovine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FACBC</title>
            <description>FACBC: Drug is give intravenously over 2 minutes at time of scan</description>
          </group>
        </group_list>
        <measure>
          <title>Target-to-background Ratio (TBR) of Anti-3-[18F]FACBC for Blood Pool</title>
          <description>To evaluate uptake mechanisms of anti-3-[18F]FACBC, target-to-background ratio (TBR) of anti-3-[18F]FACBC is assessed</description>
          <units>SUVmax</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FACBC</title>
          <description>FACBC: Drug is give intravenously over 2 minutes at time of scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Schuster, David</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-4859</phone>
      <email>dschust@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

